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1. Stimulation of adenylate cyclase 
The role of GTP in the stimulation of adenylate 
cyclase has received intense attention i  the last 
10 years. A number of excellent reviews of this area 
have appeared [1-3]. As a prelude to a discussion of 
inhibition of adenylate cyclase it seems appropriate 
to present abrief perspective on stimulation of 
adenylate cyclase. 
Many hormones interact with cell surface receptors 
to transmit a stimulatory signal to the catalytic unit 
of adenylate cyclase through the intervention of a 
GTP-regulatory protein (termed Ns) +. By a mecha- 
nism that remains unclear (due largely to a limited 
knowledge of the components of the system), GTP 
both decreases the affinity of hormones for their 
receptors and synergistically amplifies hormonal 
stimulation of activity. In general, the non-hydrolys- 
able GTP analogue, Gpp(NH)p, promotes the latter 
action more effectively than the native compound. 
These and allied findings have led to the development 
of a general hypothesis, which proposes that hormone 
binding to receptors leads to the release of previously 
bound GDP (an ineffective stimulator), which allows 
occupancy by GTP and thus attainment of a more 
active R s • N s • C complex. On hydrolysis of GTP to 
GDP, the complex reverts to an inactive form, which 
coincides with the release of hormone [1-3]. 
Considerable gaps exist in our knowledge of stim- 
ulatory adenylate cyclase systems. Quantitative infor- 
+ Abbreviations are functional ssignments, which may be 
represented by one or more distinct proteins: Rs and R i 
are receptors for hormones/neurotzansmitters evoking 
either stimulation orinhibition, respectively, of the catalytic 
activity, C; N s and N i are the GTP regulatory elements 
mediating either the stimulation orinhibition of activity, 
respectively 
mation is lacking on the relationship between hor- 
mone occupancy, GTP hydrolysis, and active com- 
plex formation. Similarly the relative stoichiometry 
of R s :N s :C is a subject for speculation. Whether the 
various elements exist in a preformed complex which 
is stabilized on interaction with regulatory ligands, or 
whether there is some degree of independent move- 
ment or collision, is unclear. Regulatory components 
in addition to those already identified may exist. For 
instance, cytoskeletal e ements are candidates for sup- 
porting roles in these systems. The number of pro- 
teins comprising the N s unit appears to be either 2 or 
3, depending on the source of the purified compo- 
nent. In addition an ADP-ribosylation factor, which 
permits the N s unit to be ADP-ribosylated by cholera 
toxin, may also be an integral component of the N s 
unit [4]. 
Notwithstanding the unanswered questions, the 
central role of the N s unit in mediating the stimulatory 
effects of hormones i clearly established and progress 
in understanding the functioning of this component 
provides ayardstick against which our understanding 
of inhibitory regulation can be evaluated. 
2. GTP-dependent inhibition of adenylate cyclase 
Early observations on fat cell membranes indicated 
that GTP at >1/aM could reduce adenylate cyclase 
activity [5-7]. Evidence had also been accumulating 
that cyclic AMP production could be decreased by a 
number of agents, such as adenosine and PGE1 in 
adipocytes [8], or norepinephrine in platelets [9]. 
Isolated reports demonstrated that adenylate cyclase 
activity could be inhibited in various broken cell 
preparations by, for instance, musearinic eholinergic 
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drugs [10], norepinephrine [9] and opiates [11]. 
These observations were drawn together when it was 
shown that inclusion of GTP in concentrations 
exceeding those required for the stimulation of 
adenylate cyclase by hormones, permitted inhibi- 
tion of the enzyme by various putative neurotrans- 
mitters, for instance, pinephrine in platelets [12] 
and in neuroblastoma × glioma hybrids [13] and 
adenosine in fat cells [14]. The GTP requirement for 
these effects clearly established adenylate cyclase 
inhibition as a receptor-mediated event which was 
somewhat nalogous to the stimulation of adenylate 
cyclase by hormones. 
Indications that distinct GTP regulatory proteins 
might mediate stimulation and inhibition of adenylate 
cyclase came from a series of studies with the fat cell. 
This enzyme displayed a pronounced biphasic 
response to GTP; GTP up to 40 nM increased activity. 
The non-hydrolysable analogue Gpp(NH)p did not 
share the inhibitory response [ 16]. Treatment of fat 
cell membranes (or cells prior to membrane prepara- 
tion) with either trypsin [15] or cholera toxin and 
NAD, or assaying in the presence of Mn 2÷ resulted in 
the abolition of the inhibitory response to GTP. In 
contrast, reatment of membranes with p-hydroxy- 
mercuriphenylsulphonic ac deliminated stimulation 
but retained inhibition by GTP [16]. The functional 
association between the inhibitory response to GTP 
and GTP-mediated inhibition by adenosine analogues 
was established by the observation that conditions 
which eliminated inhibition by GTP also led to the 
loss of the ability of adenosine analogues to inhibit 
the enzyme in a GTP-dependent manner [16]. 
Common features shared by most of these systems 
are as follows*: 
(i) Biphasic GTPkinetics are almost always encoun- 
tered (in the absence of Na ÷) [31]; 
(ii) GTP concentrations beyond those in the stim. 
ulatory range (,-,10 -7 M)promote inhibition by 
putative neurotransmitters and related com- 
pounds [30"31]; 
(iii) Where GTP, in the absence of other ligands 
causes a decrease in activity, Na ÷ (up to 100 mM) 
reverses this effect [22]; 
(iv) Na + amplifies inhibition by ligands in direct 
proportion to its reversal of the inhibition pro- 
moted by GTP alone [17,22]; 
(v) Gpp(NH)p does not promote inhibition by 
inhibitory hormones or neurotransmitters, ven 
when it evokes a transient inhibition at early 
incubation times [31.32]; 
(vi) Inhibition by neurotransmitters is generally 
<60%, except when directed against basal activ- 
ities when it may reach 80%; 
(vii) Where multiple inhibitory effectors operate, 
their effects are non-additive [ 13,22,32]; 
(viii) As with stimulatory ligands, the binding of 
inhibitory ligands is modulated by GTP (see 
section 4); 
(ix) Sodium ion and Gpp(NH)p modulate binding 
of inhibitory ligands, even though these agents 
may not affect he ability of the inhibitory 
ligands to attenuate activity (see section 4). 
Little deviation from these general properties i
encountered in a wide range of dually regulated sys- 
tems. 
3. Dually regulated adenylate cyclase systems 
A rapid growth in reports of GTP-mediated inhibi- 
tion of adenylate cyclase by many putative neuro- 
transmitter receptors has occurred in recent years. 
These include opiate [ 17], muscarinic cholinergic 
[18], ct2-adrenergic [15] in neuroblastoma X glioma 
hybrids; muscarinic cholinergic in myocardium [19, 
20]; dopamine (via a D2 receptor) in intermediate 
pituitary [21 ];adenosine, PGEI and nicotinic acid in 
adipocytes [22-24]; a2-adrenergic in platelets [12, 
25]; opiate and adenosine in hippocampus [26]; 
opiates in striatum [27,28]; angiotensin and a2-adren- 
ergic in liver [29]; and adenosine inbrain cortex [30]. 
4. Receptor binding of inhibitory ligands 
Extensive studies have been performed on the 
binding of inhibitory ligands to their receptors. The 
early studies of Pert and Snyder [33] on the binding 
of opiates to brain receptors provided valuable insights 
for later studies on the inhibition of adenylate cyclase 
by opiates. In particular, monovalent cations (most 
effectively sodium) were shown to increase the recep- 
tor binding of antagonists and decrease that of agonists. 
* The summary ofthe properties ofdually regulated a enylate 
cyclase systems is drawn from studies in many laboratories. 
Detailed references are available inthe review articles cited 
in this section 
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Subsequently, Blume [17] found that Na ÷ amplified 
the inhibition of adenylate cyclase in neuroblastoma X 
glioma hybrid by opiates. Sodium ions have now been 
shown to modify the binding of inhibitory ligands in 
diverse systems, even in the absence of an effect of 
sodium on inhibition of adenylate cyclase by these 
ligands. For instance, in platelets, a decrease in the 
affinity at the a-adrenergic receptor was encountered 
[34,35], whereas the cation did not modify the inhi- 
bition by epinephrine of the adenylate cyclase activ- 
ity [31,32]. This observation is readily understood in
view of the lack of inhibition by GTP in the absence 
of inhibitory ligand. In the fat cell, a striking effect of 
sodium on inhibition is seen due to the marked inhi- 
bition of enzyme activity by GTP in the absence of 
inhibitory ligand [22,31 ]. The retention of a Na ÷ 
effect on binding in situations where it shows no 
effect on activity may indicate separate loci for these 
2 regulatory events; alternatively, an excess of recep- 
tors over catalytic elements would permit discrepant 
regulation of receptor binding and the function medi- 
ated by the receptors. 
The sodium effect on binding is not constant with 
respect to all inhibitory ligands. For instance, inbrain, 
the binding of both opiate agonists and antagonists is 
regulated by sodium [36]; whereas only a-adrenergic 
agonist binding is modified [37]. In contrast to the 
monovalent cations, Mg 2÷ generally increases agonist 
affinity [34,38]. 
Guanine nucleotides are more consistent in the 
regulation of the binding of inhibitory ligands. GTP 
and Gpp(NH)p generally decrease the affmity of 
inhibitory ligands for their receptors [34,38]. This is 
directly analogous to the effects of guanine nucleo- 
tides on the binding of stimulatory ligands to their 
receptors. However, this observation conflicts with 
the inability of the non-hydrolysable GTP analogue 
to promote inhibition of adenylate cyclase. It might 
have been anticipated that, since only GTP, and not 
Gpp(NH)p, can promote adenylate eyclase inhibition 
by these ligands, the latter compound might not have 
shared the ability of GTP to modulate binding. The 
fact that this prediction isnot fulfilled again raises 
the possibility of either separate loci for the regulation 
of binding compared with function or an excess of 
inhibitory receptors not in association with catalytic 
activity, which permits discrepant regulation of total 
binding compared with a small pool of receptors asso- 
ciated with the enzyme. 
In tissues where it has been studied it appears that 
Mg 2÷ can modify the effect of guanine nucleotides on 
inhibitory ligand binding. In both brain (t~-adrenergic 
receptor binding) and fat cell membranes (adenosine 
receptor binding) at low magnesium concentrations, 
GTP increases the number of binding sites for the 
inhibitory ligands, whereas at higher cation concen- 
trations, GTP decreases aff'mity for the ligands ([38], 
Cooper and Gill, in preparation). 
The apparently wide diversity which exists in the 
regulation of the binding of inhibitory ligands to their 
receptors compared with that of stimulatory agents 
underlines our rather primitive understanding both of 
the interaction of inhibitory receptors with the puta- 
tive inhibitory GTP regulatory components and of 
the precise transduction mechanisms which translate 
the binding event into an inhibitory response. 
5. The role of GTP hydrolysis in inhibition of 
adenylate eyelase 
The most persuasive vidence that GTP-hydrolysis 
plays a role in hormonally-mediated inhibition of 
adenylate cyclase is the observation that Gpp(NH)p, 
the non-hydrolysable analogue, will not promote 
inhibition under any assay conditions. A characteristic 
of dually regulated systems i a transient inhibitory 
response to low concentrations of Gpp(NH)p [7,26, 
31,39]. Under such conditions, in the absence or 
presence of Na ÷, inhibitory ligands will not affect 
activity. An obvious interpretation f this widely 
encountered fmding is that GTP hydrolysis i an abso- 
lute requirement for inhibition. The hydrolysis prod- 
uct, GDP, is not required since GDP (or GP(CH2)P), 
under conditions where care is taken to prevent pbos- 
phorylation to the triphosphate, will not promote 
inhibition ([31 ], Cooper and Schlegel, unpublished). 
These observations contrast with the ready interchange 
of GTP with Gpp(NH)p in stimulation of adenylate 
cyclase, where GTP hydrolysis seems not to be a strin- 
gent requirement for enzyme stimulation. 
Supportive vidence for an obligatory role for GTP 
hydrolysis i available from studies with cholera toxin. 
As mentioned in section 2 cholera toxin treatment 
abolishes both GTP inhibition and that promoted by 
adenosine ina GTP-dependent manner in fat cell mem- 
branes [16]. Cholera toxin invariably enhances hor- 
monal stimulation i stimulatory systems by a mech- 
anism believed to involve the inhibition of a specific 
GTPase activity associated with the stimulatory (Ns) 
unit. Consequently, the observations with the fat cell 
159 
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could be interpreted to imply that toxin treatment 
also inhibited a GTPase activity associated with the 
inhibitory (Ni) unit. However, this effect of cholera 
toxin is not universally encountered in dually regulated 
systems. Inhibitory effects were retained following 
toxin treatment of Chinese hamster ovarian, neuro- 
blastoma X glioma hybrid ceils and platelets [40-42]. 
In neuroblastoma × glioma and platelet mem- 
branes, a GTPase activity has been detected which 
can be stimulated by opiates and a-adrenergic agents, 
respectively [43,44]. Substrate specificities were not 
examined in these studies, thus a specific GTPase 
activity was not unequivocally demonstrated. Never- 
theless, a 2-fold stimulation was achieved, and it is 
tempting to speculate that the GTPase activity mea- 
sured is relevant to the inhibition of adenylate cyclase 
mediated by the receptors in these tissues. The rather 
complex assay mixtures involved may allow trans- 
phorylation of the terminal phosphate of GTP to 
ATP, which is also included in the assay. Neither group 
has attempted todetermine the source of the Pi released 
into the medium, therefore the possibility must be 
considered that inhibitory ligands may also be capable 
of stimulating an ATPase activity in plasma membranes 
in an analogous manner to that reported for insulin 
and catecholamines [45,46]. 
However, notwithstanding the reservations raised 
concerning these studies, the accumulated evidence 
from more indirect studies would have anticipated a 
more central role for a GTPase in inhibitory regulation 
than in the case of stimulatory regulation. 
6. The relationship between N s and N i 
Definitive vidence islacking on whether Ns and N i 
are distinct proteins or merely functional notations. 
The broadly descriptive options which might be con- 
sidered include: 
(i) That the N unit (or complex, see section 1) is 
constant in all adenylate cyclase systems and that 
the functions associated with N s and N i merely 
reflect he association of the N unit with R s or 
Ri, respectively; 
(ii) N s and N i are distinct regulatory protein com- 
plexes which share a common catalytic unit; or 
(iii) N i may be a modified form of N s (e.g., an oligo- 
meric form, an association with an exogenous fac- 
tor or protein, such as calmodulin) which may or 
may not be stabilised or promoted upon interac- 
tion with R i. 
Differences in properties between the functional 
entities referred to as N s and N i are summarised in 
table 1. These differences justify the functional assign- 
ments and, with other evidence discussed herein, sup- 
port the view that fundamental differences exist 
between the 2 regulatory systems. Nevertheless a full 
appreciation of their properties will become available 
only by further structural studies. 
7. Structural studies on dually regulated adenylate 
cyclase systems 
Apart from the preliminary studies on the fat cell 
Table 1 
Summary of  the properties associated with the 2 GTP regulatory functions 
Property N s N i 
GTP requirement (EDso) 10 nM, 1 ~tM a 1 jaM (3) 
Sodium ions - - t (4) 
Cholera toxin t - ,~  (3) 
Me 2+ "~ ~ (3) 
Gpp(NH)p ~ - ,~ (3,4) 
Cholera toxin-labeled bands 1 or 2 Additional bands (8) 
Mild trypsin treatment ~, -  - ,$  (3) 
Effect of  GTP, Gpp(NH)p 
on binding ~ K d ~ Kd, t R (5) 
GTP on basal cyclase - , t  ~ (3) 
Sodium effect on binding - ~ K d (5) 
a When stimulatory systems are considered 
Notations: - ,  no effect; t amplification of  the function; ~, dampening of  the 
function; numbers in parenthesis refer to sections where these features are dis- 
cussed 
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indicating selective abolition and retention of 1 of the 
2 effects mediated by GTP (see section 4), most atten- 
tion has focussed on the receptors in dually regulated 
systems. 
For instance, opiate receptors have been solubilized 
with full retention of their agonist specificity [47]. 
Another solubilised opiate receptor preparation retained 
the ability of Na ÷ to modify binding [48], although 
no effects of GTP were detected. This important 
observation suggests that the sodium site may be asso- 
ciated with the receptor rather than the GTP regulatory 
unit. 
The ~-adrenergic receptor from liver has been solu- 
bilised and partially purified [49]. The irreversibly 
binding antagonist, phenoxybenzamine, wasutilised 
to monitor the presence of the receptor through vari- 
ous purification procedures. Although phenoxyben- 
zamine cannot readily be removed from the receptor 
preparation, this material is quite suitable for gener- 
ating antibodies which may be utilised to identify and 
purify unoccupied receptors. 
Prior incubation of platelet plasma membranes 
with a2-adrenergic agonists tabilises a higher M r form 
of the receptor than that observed following incuba- 
tion with antagonists. This data may suggest that 
agonists tabilise interaction between receptor and N i 
unit [50]. 
adenosine. Addition of calmodulin restores the effect 
[26]. This behaviour does not seem to be generally 
applicable to inhibitory Systems ince the platelet and 
fat cell systems, for instance, are not affected by EGTA 
treatment [31 ]. However, in the case of the hippo- 
campal system (and possibly other neural systems), 
calmodulin may provide ameans for identifying inhib- 
itory components. 
7.3. Ultrastructural studies 
Recent microscopic studies indicate that both 
opiate and cholinergic receptors occur in clusters on 
the cell surface [52,53]. Irradiation inactivation studies 
also indicated that very large structures mediated stim- 
ulation and inhibition of fat cell adenylate cyclase 
[54]. Such a situation is readily envisaged in view of 
the multiplicity of stimulatory and inhibitory neuro- 
transmitters converging on a common pool of catalytic 
activity (see section 3). These structures, which if 
composed of heterogenous stimulatory and inhibitory 
receptors with their associated N units, would resemble 
multi-enzyme complexes and provide a ready means 
of achieving the non-additive stimulation and inhibi- 
tion of adenylate cyclase by different neurotransmit- 
ters discussed in section 3. 
8. Future directions 
7.1. Cholera toxin 
Since cholera toxin with NAD modifies the func- 
tions ascribed to both N s and Ni, it is conceivable that 
with [a2p]NAD, protein bands additional to those 
encountered in stimulatory systems might be detected 
on SDS electrophoresis following exposure to the 
toxin of dually regulated systems. When a range of 
plasma membrane preparations were compared, those 
subject o dual regulation showed additional labelled 
bands; in fat cell and CHO, a 52 000 and a 54 000M r 
band were detected; in platelet a 58 000 band was 
detected, inaddition to the widely observed 42 000M r
band [51 ]. The relationship of these additional pro- 
teins to the N s unit remains to be established. 
7.2. Calmodulin 
The hippocampal denylate cyclase is a dually 
regulated system (section 3), which can be inhibited 
by opiates and adenosine analogues in a GTP-depen- 
dent manner. Calmodulin appears to play a role in 
this system, since its removal by EGTA treatment 
results in the loss of inhibition by the opiates and 
A number of putative neurotransmitters and pep- 
tides which have been identified in brain as yet do 
not have a measurable function in isolated membrane 
preparations. It seems likely that some of these com- 
pounds, including histamine, serotonin, GABA, gluta- 
mine, ACTH, substance P, o~-MSH, will turn out to 
utilise GTP inhibitory pathways. 
Whether the catalytic unit of adenylate cyclase is 
the same in dually regulated as in stimulatory systems 
must be determined. It is conceivable that the com- 
plexity of catalytic units varies as a function of the 
degree of regulation to which they are subject. 
Further progress in understanding the structural 
nature of these systems will require a combination of 
approaches, including ultrastructural studies, solubili- 
sation and reconstitution f components, identifica- 
tion of mutants lacking one or other of the regulatory 
elements, coupled with the fusion/complementation 
approach pioneered by Orly and Schramm [55]. 
A perplexing question, which must reflect a funda- 
mental property of inhibitory systems, arises from the 
partial inhibition evoked by inhibitory neurotransmit- 
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ters. Since inhibition ranges from 20-80% maximally 
[31,32], the physiological significance of this regula- 
tion may be doubted. However, partial inhibition of 
adenylate cyclase combined with the presence of 
phosphodiesterase in intact cells can result in substan- 
tial reduction ofintraceUular cAMP levels. The striking 
inhibition of cAMP production in the fat cell by 
adenosine and its analogues (leading to a marked inhi- 
bition of lipolysis) and in platelets by epinephrine 
(resulting in platelet aggregation) must reflect such a 
situation. 
The f'mding of angiotensin II- and a-adrenergic- 
inhibition of adenylate cyclase in liver [29], which 
had been considered a simple stimulatory system, 
raises ome intriguing possibilities. Inclusion of high 
concentrations of EDTA was required uring all stages 
of the preparation of the plasma membranes for the 
observation of this effect. Now, it has long been 
known that both GTP and Na ÷ would effect angiotensin 
binding to adrenal cortex membranes [56] (without 
EDTA treatment). Thus the possibility is raised that 
an RN complex existed for angiotensin which had not 
been linked to adenylate cyclase, but to some other 
process, prior to the chelator treatment. Certainly a 
numb er of receptors mediating inhibition o f adenylate 
cyclase have also been implicated in either calcium 
transport or phosphatidylinositol metabolism, e.g., 
muscarinic holinergic, a2-adrenergic and angiotensin 
[5 7]. The findings discussed above raise the possibility 
that switching of the function served by an RN com- 
plex can occur physiologically in addition to the experi- 
mental means presented above. 
In [5 8] increased adenylate cyclase activity was 
described following prolonged exposure of neuro- 
blastoma X glioma hybrid cells to morphine without 
alteration in receptor number. The situation was 
presented as a model system for tolerance and addic- 
tion to opiates. Current appreciation of the existence 
of stimulatory and inhibitory GTP regulatory protein 
interactions may provide an understanding for the 
basis of this observation. 
Receptor-mediated inhibition of Gpp(NH)p-acti- 
vated adenylate cyclase activity by progesterone in 
Xenopus oocytes and by a-mating factor in yeast 
[59-61] has been reported. In both cases funda- 
mental developmental changes correlate with these 
inhibitions. It is possible that modified forms of 
N i with less severe restrictions on the terminal diphos- 
phate bond of the guanine nucleotide mediate these 
effects. 
~ H  ~ I Na* 
P Me2* 
CHOLERA ,( N~ 1 ~ ~ ~"~l Ni ~. CHOLERA TOXIN ~.~ ~-  TOX'N 
PMS /
Fig.1. Schematic representation f dually regulated adenylate 
cyclase with suggested sites of action of various regulators. In
this scheme broken arrows indicate inhibition or suppression 
of a process; olid arrows indicate promotion or enhancement 
of a process; the heavy directional lines between R and N 
units indicate the guanine nucleotides which promote com- 
munication from R to N or from N to R. PMS,p-hydroxy- 
met curipheylsulphonate. 
9. Conclusions 
A schematic model (rigA) summarises the functional 
components involved in dual regulation of adenylate 
cyclase and the site of action of some modifiers of 
activity. The central role of GTP is evident. Apprecia- 
tion of the potential importance of GTP has proven 
to be the key to our current appreciation of these sys- 
tems. Evidence is accumulating that separate GTP- 
regulatory proteins are associated with inhibition and 
stimulation from measurements of both activity and 
regulation of binding to the 2 classes of receptor. The 
next few years will see increasing appreciation not 
only of the physiological importance, but also insights 
into the structural elements of these systems. 
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